oshicasinonodepositbonus| The Hong Kong stock pharmaceutical sector fell sharply, with the Hang Seng Pharmaceutical ETF falling more than 4%, continuing to premium during the session

the news point of viewoshicasinonodepositbonus, Kangfang Biotech clinical data fell short of expectationsoshicasinonodepositbonus, the stock price dropped more than 30%, driving the Hong Kong stock pharmaceutical sector to fall sharply in early trading today (May 24, 2024). Keji Pharmaceutical, Baiji Shenzhou, Zaiding Pharmaceutical and other collective adjustments, and the Hang Seng Pharmaceutical ETF (159892) fell more than 4%.

In addition, the minutes of the Federal Reserve's meeting were biased, and expectations for interest rate cuts fell again. Hong Kong stocks and pharmaceuticals, which are sensitive to the investment and financing environment, were greatly affected. The Hang Seng Biotech Index also fell more than 5% during the session.

The above content and data have nothing to do with the position of Lianyun Channel on the interface and do not constitute investment advice. Operate accordingly and bear the risks at your own expense.